Stifel Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis initiates coverage on Alto Neuroscience (NYSE:ANRO) with a Buy rating and a price target of $32.
February 27, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Paul Matteis has initiated coverage on Alto Neuroscience with a Buy rating and set a price target of $32.
The initiation of coverage by Stifel with a Buy rating and a significant price target suggests a positive outlook on ANRO's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100